All the news

People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ...

Adding a cholesterol-lowering drug to direct-acting antivirals (DAAs) prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director of the Toronto Centre for ...

Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at the AASLD Liver Meeting this week in Boston, aiming to advance ...

A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ...

Direct-acting antiviral treatment for hepatitis C need not be delayed until the completion of treatment for hepatocellular carcinoma (HCC; liver cancer), but people with hepatitis C need to be warned of a ...

Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ...

Sci-B-Vac, an investigational vaccine that contains three different hepatitis B virus (HBV) proteins, may offer more protection, especially for older adults, than widely used existing vaccine options, according to late-breaking study results presented ...

An experimental two-part vaccine was not able to prevent chronic hepatitis C virus (HCV) infection in a mid-stage study, according to a presentation at the recent IDWeek 2019 conference in Washington, DC. Prof. Andrea ...

Seventy-eight per cent of people using needle and syringe programmes in community pharmacies in London who opted to test for hepatitis C would prefer to receive their hepatitis C treatment from the ...

Obesity without non-alcoholic fatty liver disease (NAFLD) does not raise the risk of cancer, but people with NAFLD who are also obese are almost twice as likely to be diagnosed with cancer ...